Bioxytran, Inc., a clinical-stage pharmaceutical company, reported positive Phase 2 results for its lead COVID-19 treatment candidate, ProLectin-M, confirming rapid viral clearance and safety. Concurrently, the company continues advancing BXT-25, an acellular oxygen carrier targeting hypoxic tissue treatment. While recent private placements have provided roughly $1.2 million in liquidity, Bioxytran faces significant financial pressure with limited current assets versus liabilities. The company’s business model remains focused on progressing novel carbohydrate-based drug candidates through clinical trials with a licensing commercialization strategy. Critical near-term growth depends on successful trial completions, regulatory approvals, and additional financing to sustain operations.